Thank you, Mindy, for your questions and thanks for joining. So two questions, the first question on the COVID impact on the business. I think -- on two sides of things, right? I think first side of things would be from a business operational perspective. I think that we are not as affected by the emergence of COVID than maybe some of the more traditional offline agencies or brokerages, because most of our activities are done online, as you know. However, I think that the more pertinent point to make is that the Omicron outbreak has really dampened income expectations of the average consumer in China. And also I think that it also has, unfortunately, let to quite massive layoffs in the economy across different industries. And so I think that the major impact of Omicron on the industry really has to do with the consumers' confidence and the consumers' ability or willingness to consume any insurance products, which as we all know insurance product is non-essential item in a way, it's the more discretionary of all financial products available, compared to things like securities or fixed income product, I think. And therefore, I think that the major impact Omicron has is on the demand side of the industry, and it has been very, very weak in the first two quarters as we can also take reference from the FYP numbers of the major insurers in China and also from the other brokerages and third-party intermediaries. So that will be the answer to the first question. And for the second question on HFCAA and the delisting risk, I think that the market has somewhat absorbed all of this news flow already by now. I think most of the Chinese companies that are listed in the U.S. ADR markets has already gone on this list. And I think from the company standpoint, what we would like to make as a statement is that we continue to maintain our listing in the U.S. and we will take all the steps that is required to make sure that we will state our shareholders interest and shareholder value. And obviously, we'll be looking into measures, including potential secondary delisting in Hong Kong in order to somehow hedge this risk of the delisting scenario. And I think that we also have seen some encouraging signs in the news reporting on the collaborative efforts between the two sides of the regulators table from the China side and also on the U.S. side in terms of progressing on the PCAOB issues on on-site inspection of audits, et cetera. I think, frankly, this is somewhat of the corporate level of control, but we remained optimistic on a resolution of the matter between the two sides, and we on our own level, we'll continue to take all measures in order to safeguard shareholders' interest.